Bacteriophages Are Capable of Selectively Killing Bacteria Without Harming Human Cells
The primary rationale for using bacteriophages as a therapeutic option for antimicrobial-resistant (AMR) infections is their ability to selectively target and kill specific bacterial pathogens without harming human cells or disrupting the normal microbiota. This fundamental characteristic distinguishes phages from broad-spectrum antibiotics and makes them particularly valuable in the era of escalating antimicrobial resistance 1.
Core Mechanism: Bacterial Specificity
Bacteriophages are viruses that exclusively infect bacteria—they cannot infect human cells. This inherent selectivity means:
- Targeted bacterial clearance occurs with minimal impact on commensal microbiota 2
- Human cells remain unaffected because phages lack the cellular machinery to recognize or enter mammalian cells
- Precision antimicrobial action allows treatment of resistant infections while preserving beneficial bacteria 3
The evidence demonstrates that phage therapy has become "a promising solution for persistent and resistant bacterial infections" specifically because phages can be matched to target the isolated pathogen without collateral damage to the host 1.
Additional Therapeutic Advantages
While selective bacterial killing is the primary rationale, phages offer complementary benefits:
Synergy with Antibiotics
Phages can be combined with antibiotics to enhance treatment effectiveness 1. The Clinical Phage Microbiology framework specifically recommends assessing "suitable concomitant antibiotic regimens" through phage-antibiotic checkerboard testing 1. This combination approach can restore antibiotic susceptibility through evolutionary trade-offs, where bacterial resistance to phages may increase antibiotic sensitivity 4.
Biofilm Activity
Phages demonstrate ability to disrupt bacterial biofilms 2, though this is a secondary characteristic rather than the primary rationale. The Clinical Phage Microbiology pipeline includes specific biofilm evaluation for "clinical cases requiring special consideration" 1.
Not Broad-Spectrum
Importantly, phages are NOT broad-spectrum agents—they are highly specific, typically targeting individual bacterial species or even specific strains 1, 2. This specificity is actually an advantage for preserving the microbiome but requires precise matching of phage to pathogen through susceptibility testing 1, 5.
Clinical Implementation
The evidence emphasizes that successful phage therapy requires:
- Precise phage-bacterial matching through standardized susceptibility testing rather than empirical selection 1, 5
- Individual bacterial isolate screening against phage banks using plaque assays and growth kinetics 1
- Monitoring for resistance emergence during treatment with readiness to adjust therapy 1
Recent clinical evidence shows phage therapy consistently reduces bacterial loads by 0.4-5.0 log₁₀ CFU with favorable safety profiles and no severe adverse events reported 6, 7.
Critical Distinction
The question's option about "broad-spectrum antibiotics targeting multiple bacterial species" is incorrect—this fundamentally misrepresents phage biology. Phages are narrow-spectrum, species-specific or strain-specific agents 2. Their therapeutic value lies precisely in this selectivity, not in broad coverage.